Enanta Pharmaceuticals In... (ENTA)
4.94
0.10 (2.07%)
At close: Jan 15, 2025, 10:44 AM
Company Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Mar 21, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Dr. Jay R. Luly Ph.D. |
Contact Details
Address: 500 Arsenal Street Watertown, Massachusetts United States | |
| Website | https://www.enanta.com |
Stock Details
| Ticker Symbol | ENTA |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001177648 |
| CUSIP Number | 29251M106 |
| ISIN Number | US29251M1062 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay R. Luly Ph.D. | President, Chief Executive Officer & Director |
| Matthew P. Kowalsky J.D. | Chief Legal Officer |
| Brendan Luu | Chief Business Officer |
| Dr. Scott T. Rottinghaus M.D. | Senior Vice President & Chief Medical Officer |
| Dr. Yat Sun Or Ph.D. | Senior Vice President of Research & Development and Chief Scientific Officer |
| Jennifer Viera | Senior Director of Investor Relations & Corporate Communications |
| Nathaniel S. Gardiner J.D. | Consultant |
| Paul J. Mellett Jr. | Chief Financial & Administrative Officer |
| Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |